Targeting T cell cancers with specific antibodies
TCR Targeting Antibodies for the Treatment of T cell Cancers
This study is working on a new type of treatment for people with T cell cancers, like leukemias and lymphomas, by using special antibodies that can target and attack the cancer cells without harming the healthy ones, aiming to improve survival rates for those who have had a relapse.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11011254 on NIH RePORTER |
What this research studies
This research focuses on developing targeted immunotherapies using antibodies to treat T cell cancers, which include T cell leukemias and lymphomas. The approach involves creating bispecific antibodies that can selectively target cancerous T cells while preserving healthy T cells in the immune system. By distinguishing between T cells based on their T cell receptor (TCR) types, the research aims to improve treatment outcomes for patients with relapsed T cell cancers, which currently have low survival rates. The methodology includes in vitro testing of these antibodies to evaluate their effectiveness in killing cancer cells while sparing healthy cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with T cell leukemias or lymphomas, particularly those who have relapsed after standard treatments.
Not a fit: Patients with non-T cell cancers or those who do not have a specific T cell receptor type may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with T cell cancers.
How similar studies have performed: Previous research has shown promise in using targeted antibody therapies for various cancers, indicating potential success for this novel approach in T cell cancers.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Paul, Suman — Johns Hopkins University
- Study coordinator: Paul, Suman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.